身体功能和严重的副作用对RA患者 (<5年) 最重要:一个离散选择实验评估个性化RA治疗偏好
Karin Schölin Bywall1,2, Bente Appel Esbensen3,4, Marie Heidenvall5
1School of Health, Care and Social Welfare, Division of Health and Welfare Technology, Mälardalen University, Västerås, Sweden. karin.scholin.bywall@mdu.se.
BMC rheumatology
|July 3, 2023
概括
患有类风湿性关节炎 (RA) 的患者优先考虑改善身体功能或降低严重副作用风险. 了解这些不同的偏好是 RA 管理中个性化治疗决策的关键.
科学领域:
- 类风湿病学 类风湿病学
- 精准医学是一门精准的医学.
- 健康心理学 心理健康心理学
背景情况:
- 在风湿性关节炎 (RA) 个性化精密医学中,共享决策至关重要.
- 早期评估患者的偏好可以指导RA患者的治疗选择,RA患者对初始疗法反应不足.
研究的目的:
- 评估类风湿性关节炎 (RA) 患者的治疗偏好,疾病持续时间少于5年.
- 为了确定患者在RA治疗中对功能能力和副作用概况的偏好.
主要方法:
- 在瑞典,对182名RA患者进行了离散选择实验 (DCE).
- 使用随机参数逻辑和潜伏类分析模型来分析患者的偏好和异质性.
主要成果:
- 患者优先考虑改善身体和心理社会功能能力,减少副作用.
- 两种不同的偏好模式出现了:一种优先考虑减少严重副作用的风险,另一种优先考虑身体功能能力.
结论:
- 在RA患者的决策中,重点是提高身体功能或尽量减少严重副作用的可能性.
- 这些发现强调了评估个体患者偏好的重要性,以优化RA治疗讨论中的共享决策.
相关概念视频
Rheumatic Heart Disease III: Medical Management
22
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
22
Rheumatic Heart Disease IV: Nursing Management
23
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
23
Inflammatory Bowel Disease IV: Pharmacological Management
155
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
155
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
156
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
156
Drug Therapy
74
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
74
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
175
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
175


